The Wall Street Journal was bang on the money with its recent scoop about Johnson & Johnson move on US-listed medical device maker Shockwave Medical.
The terms of the deal have just been announced and I have pasted the link below if you want to real all of the details of the transaction:..
Little old Betaville is in another grump.
Why?
Well, I was chasing down the takeover rumours circulating about Shockwave, the US-listed medical device company, and just as I was about to publish an alert rivals at the Wall Street Journal pumped out their scoop about Johnson & Johnson's bid for the company. Below is a link to WSJ's scoop:..
A string of US-listed biotechnology deals have been announced today.
They include: Boston Scientific's $3.7 billion acquisition of US-listed medical technology company Axonics and Merck's $680 million takeover of Harpoon Therapeutics.
Also, announced today was Johnson & Johnson's $2 billion acquisition of US-listed biopharmaceutical company Ambrx. Below is the link to that deal announcement:..
Johnson & Johnson is splashing out $16.6 billion for Abiomed Inc, a medical technology company.
The American healtchare giant is making an upfront payment of $380 in cash and is also offering $35.00 per share in cash if certain commercial and clinical milestones are achieved.
That's a premium of over 50pc for Abiomed Inc!
Below is a link the press release:..
It would appear Johnson & Johnson was also circling US-listed Global Blood Therapeutics, which two weeks ago agreed a deal to sell itself to pharmaceutical giant Pfizer for $5.4 billion.
Well, that's according to arch rivals at Bloomberg. Below is a link to the Bloomie story that came out overnight:..
Bloomberg last night "broke" the story about French drugs company Sanofi considering a counter offer for Swiss biopharmaceutical group Actelion. Here is the link:
Actelion has just confirmed it has received a £17 billion takeover approach from Johnson & Johnson. Meanwhile, Dominic O'Connell, former The Sunday Times business editor and now a presenter on Radio 4, has just Tweeted this:..
Actelion is currently up just over 15pc and various hacks are claiming the "scoop" despite the fact the story hasn't even made into hard newsprint yet in one of the "newspapers of record" (Financial Times, Wall Street Journal, The Daily Telegraph etc) or been confirmed by the Swiss company itself...